{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:59:50Z","timestamp":1790312390183,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.leukres.2026.108322","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:09:35Z","timestamp":1789830575000},"page":"108322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cladribine and low-dose cytarabine as first salvage after hypomethylating agent and venetoclax in acute myeloid leukemia"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3384-9161","authenticated-orcid":false,"given":"Ritika","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2444-0862","authenticated-orcid":false,"given":"Claire","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1665-7782","authenticated-orcid":false,"given":"Edna","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asiri","family":"Ediriwickrema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Fakhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-5850","authenticated-orcid":false,"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Shomali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8202-0870","authenticated-orcid":false,"given":"Gabriel N.","family":"Mannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108322_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108322_bib2","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.3390\/jcm14082759","article-title":"Intensive chemotherapy versus venetoclax-based regimens in elderly patients with acute myeloid leukemia: is the chemotherapy era ending?","volume":"14","author":"Farina","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.leukres.2026.108322_bib3","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-6","article-title":"Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","volume":"146","author":"Fathi","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108322_bib4","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Abhishek Maiti","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2026.108322_bib5","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","article-title":"Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy","volume":"108","author":"Gangat","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2026.108322_bib6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108322_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100038","article-title":"Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia","volume":"1","author":"Chin","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.leukres.2026.108322_bib8","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108322_bib9","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","article-title":"Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial","volume":"5","author":"Kadia","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2026.108322_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-024-00982-3","article-title":"Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed\/refractory acute myeloid leukemia: results of a pilot study","volume":"14","author":"Li","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108322_bib11","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.284962","article-title":"Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent","author":"Steinauer","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2026.108322_bib12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","article-title":"Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions","volume":"87","author":"Gandhi","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108322_bib13","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2026.108322_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2026.108322_bib15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108322_bib16","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108322_bib17","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Acute Myeloid 3, Leukemia2025, 2026."},{"key":"10.1016\/j.leukres.2026.108322_bib18","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108322_bib19","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/cancers16061091","article-title":"Venetoclax resistance in acute myeloid leukemia","volume":"16","author":"Garciaz","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.leukres.2026.108322_bib20","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2024024245","article-title":"TP53-mutated acute myeloid leukemia: how can we improve outcomes?","volume":"145","author":"Sallman","year":"2025","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:25:47Z","timestamp":1790310347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":20,"alternative-id":["S0145212626001669"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108322","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cladribine and low-dose cytarabine as first salvage after hypomethylating agent and venetoclax in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108322"}}